Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Net Assets
Latest net assets as of September 2025: CN¥2.73 Billion CNY
Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has net assets worth CN¥2.73 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.89 Billion) and total liabilities (CN¥161.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.73 Billion |
| % of Total Assets | 94.4% |
| Annual Growth Rate | 22.87% |
| 5-Year Change | 60.9% |
| 10-Year Change | 321.82% |
| Growth Volatility | 26.0 |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below shows the annual net assets of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.46 Billion | +6.73% |
| 2023-12-31 | CN¥2.30 Billion | +13.64% |
| 2022-12-31 | CN¥2.03 Billion | +12.83% |
| 2021-12-31 | CN¥1.80 Billion | +17.57% |
| 2020-12-31 | CN¥1.53 Billion | +13.03% |
| 2019-12-31 | CN¥1.35 Billion | +35.82% |
| 2018-12-31 | CN¥995.42 Million | +24.23% |
| 2017-12-31 | CN¥801.26 Million | +22.22% |
| 2016-12-31 | CN¥655.58 Million | +12.47% |
| 2015-12-31 | CN¥582.91 Million | +13.51% |
| 2014-12-31 | CN¥513.55 Million | +103.86% |
| 2013-12-31 | CN¥251.92 Million | +38.89% |
| 2012-12-31 | CN¥181.38 Million | +42.14% |
| 2011-12-31 | CN¥127.61 Million | +41.09% |
| 2010-12-31 | CN¥90.44 Million | -19.17% |
| 2009-12-31 | CN¥111.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 144615497397.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.43 Billion | 60.81% |
| Common Stock | CN¥523.58 Million | 22.25% |
| Other Comprehensive Income | CN¥270.75 Million | 11.50% |
| Other Components | CN¥128.19 Million | 5.45% |
| Total Equity | CN¥2.35 Billion | 100.00% |
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gray Television Inc
NYSE:GTN-A
|
$894.19 Million |
|
China Suntien Green Energy Corporation Limited
PINK:CSGEF
|
$894.23 Million |
|
Chengdu Haoneng Tech Co Ltd
SHG:603809
|
$894.77 Million |
|
Gelex Group JSC
VN:GEX
|
$895.44 Million |
|
Hunan Friendship&Apollo Commercial Co Ltd
SHE:002277
|
$893.82 Million |
|
TOWA Corporation
F:TWA
|
$893.35 Million |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
$893.29 Million |
|
Nippon Light Metal Holdings Company Ltd
F:N9L
|
$893.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,185,099,454 to 2,353,706,702, a change of 168,607,248 (7.7%).
- Net income of 317,822,382 contributed positively to equity growth.
- Dividend payments of 97,447,671 reduced retained earnings.
- Other comprehensive income increased equity by 6,305.
- Other factors decreased equity by 51,773,768.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥317.82 Million | +13.5% |
| Dividends Paid | CN¥97.45 Million | -4.14% |
| Other Comprehensive Income | CN¥6.30K | +0.0% |
| Other Changes | CN¥-51.77 Million | -2.2% |
| Total Change | CN¥- | 7.72% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 105.60x to 5.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.24 | CN¥25.07 | x |
| 2010-12-31 | CN¥0.19 | CN¥25.07 | x |
| 2011-12-31 | CN¥0.27 | CN¥25.07 | x |
| 2012-12-31 | CN¥0.39 | CN¥25.07 | x |
| 2013-12-31 | CN¥0.54 | CN¥25.07 | x |
| 2014-12-31 | CN¥0.99 | CN¥25.07 | x |
| 2015-12-31 | CN¥1.11 | CN¥25.07 | x |
| 2016-12-31 | CN¥1.25 | CN¥25.07 | x |
| 2017-12-31 | CN¥1.53 | CN¥25.07 | x |
| 2018-12-31 | CN¥1.85 | CN¥25.07 | x |
| 2019-12-31 | CN¥2.43 | CN¥25.07 | x |
| 2020-12-31 | CN¥2.78 | CN¥25.07 | x |
| 2021-12-31 | CN¥3.32 | CN¥25.07 | x |
| 2022-12-31 | CN¥3.78 | CN¥25.07 | x |
| 2023-12-31 | CN¥4.17 | CN¥25.07 | x |
| 2024-12-31 | CN¥4.50 | CN¥25.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Wolwo Bio-Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.50%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.34%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.15x
- Recent ROE (13.50%) is below the historical average (20.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 9.40% | 28.10% | 0.31x | 1.09x | CN¥-673.09K |
| 2010 | 20.36% | 31.02% | 0.54x | 1.22x | CN¥9.36 Million |
| 2011 | 29.21% | 36.12% | 0.70x | 1.15x | CN¥24.51 Million |
| 2012 | 29.65% | 36.45% | 0.77x | 1.05x | CN¥35.64 Million |
| 2013 | 28.01% | 36.45% | 0.73x | 1.05x | CN¥45.37 Million |
| 2014 | 19.39% | 41.57% | 0.45x | 1.03x | CN¥48.20 Million |
| 2015 | 20.21% | 44.11% | 0.44x | 1.05x | CN¥59.53 Million |
| 2016 | 19.71% | 41.40% | 0.45x | 1.06x | CN¥63.64 Million |
| 2017 | 23.23% | 48.27% | 0.45x | 1.06x | CN¥105.98 Million |
| 2018 | 24.02% | 46.51% | 0.47x | 1.09x | CN¥135.93 Million |
| 2019 | 23.47% | 46.66% | 0.45x | 1.12x | CN¥171.20 Million |
| 2020 | 19.13% | 43.77% | 0.40x | 1.10x | CN¥132.86 Million |
| 2021 | 19.47% | 41.85% | 0.42x | 1.11x | CN¥164.38 Million |
| 2022 | 17.62% | 38.92% | 0.41x | 1.11x | CN¥150.81 Million |
| 2023 | 14.20% | 36.57% | 0.33x | 1.17x | CN¥91.67 Million |
| 2024 | 13.50% | 34.34% | 0.34x | 1.15x | CN¥82.45 Million |
Industry Comparison
This section compares Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $861,927,359
- Average return on equity (ROE) among peers: 4.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | CN¥2.73 Billion | 9.40% | 0.06x | $893.83 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $189.44 Million | 3.08% | 4.33x | $199.04 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $485.74 Million | 1.60% | 0.77x | $307.06 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $336.40 Million | 0.81% | 1.44x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $1.49 Billion | 3.37% | 0.66x | $229.65 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $1.25 Billion | 8.38% | 0.07x | $144.69 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $507.64 Million | 23.17% | 1.09x | $1.01 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $226.35 Million | 6.06% | 0.04x | $447.60 Million |
| Chongqing Lummy Pharmaceutical (300006) | $1.88 Billion | -4.66% | 0.52x | $475.43 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.39 Billion | 1.50% | 0.52x | $1.19 Billion |